WO1998051312A1 - Thiadiazinyl corticotropin-releasing factor binding protein ligand inhibitors - Google Patents
Thiadiazinyl corticotropin-releasing factor binding protein ligand inhibitors Download PDFInfo
- Publication number
- WO1998051312A1 WO1998051312A1 PCT/US1998/009861 US9809861W WO9851312A1 WO 1998051312 A1 WO1998051312 A1 WO 1998051312A1 US 9809861 W US9809861 W US 9809861W WO 9851312 A1 WO9851312 A1 WO 9851312A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkylenyl
- heterocychc
- tetrahydro
- thiadiazin
- Prior art date
Links
- 0 **(C(***1*I)=O)S1(=O)=O Chemical compound **(C(***1*I)=O)S1(=O)=O 0.000 description 11
- YZRRYMBULYCDJC-UHFFFAOYSA-N CCCCSC=C(C(N(CCc1ccc[s]1)S(N1CCc2ccc[s]2)(=O)=O)=O)C1=O Chemical compound CCCCSC=C(C(N(CCc1ccc[s]1)S(N1CCc2ccc[s]2)(=O)=O)=O)C1=O YZRRYMBULYCDJC-UHFFFAOYSA-N 0.000 description 1
- PHNVPDOOMODEAI-UHFFFAOYSA-N CCN(C(C(C(N1CC)=O)=CNCCN2CCOCC2)=O)S1(=O)=O Chemical compound CCN(C(C(C(N1CC)=O)=CNCCN2CCOCC2)=O)S1(=O)=O PHNVPDOOMODEAI-UHFFFAOYSA-N 0.000 description 1
- GCZKINFSZCSISO-UHFFFAOYSA-N O=C(C(C(N1CCc2ccccc2)=O)=CSC(c2ccccc2)(c2ccccc2)c2ccccc2)N(CCc2ccccc2)S1(=O)=O Chemical compound O=C(C(C(N1CCc2ccccc2)=O)=CSC(c2ccccc2)(c2ccccc2)c2ccccc2)N(CCc2ccccc2)S1(=O)=O GCZKINFSZCSISO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- Alzheimer's disease is a degenerative disorder of the human brain. Clinically, it appears as a progressive dementia. Its histopathology is characterized by degeneration of neurons, gliosis, and the abnormal deposition of proteins in the brain. Proteinaceous deposits (called "amyloid”) appear as neurofibrillary tangles, amyloid plaque cores, and amyloid of the congophilic angiopathy. By current estimates, over two million individuals in the United States suffer from this disease.
- corticotropin-releasing factor in Alzheimer's disease. See, e.g., Behan, et al.. Nature (London . 378:284 (1995). In brains of those afflicted with Alzheimer's disease there are dramatic (greater than 50%) decreases in corticotropin-releasing factor levels, with a reciprocal increase in corticotropin-releasing factor receptor levels in cerebrocortical areas that are affected with Alzheimer's disease, while neither corticotropin-releasing factor nor receptor levels are quantitatively changed in non-affected areas of the cortex. Bissette, et al.. Journal of the American Medical Association. 254:3067 (1985); E. DeSouza, et al.. Brain Research. 397:401 (1986); E. DeSouza, et al.. Hospital Practice. 23:59 (1988).
- Alzheimer's disease Alterations in brain corticotropin-releasing factor content have also been found in Parkinson's disease and progressive supranuclear palsy, neurological disorders that share certain clinical and pathological features with Alzheimer's disease.
- corticotropin-releasing factor content is decreased and shows a similar staining pattern similar to instances of Alzheimer's disease.
- progressive supranuclear palsy corticotropin-releasing factor is decreased to approximately 50% of control values in frontal, temporal, and occipital lobes.
- Some depressive disorders are also associated with decreased levels of corticotropin-releasing factor.
- Patients in the depressive state of seasonal depression and in the period of fatigue in chronic fatigue syndrome demonstrate lower levels of corticotropin-releasing factor in the cerebrospinal fluid.
- hypoactivation of the stress system as manifested by low levels of corticotropin-releasing factor may play a role in other disorders as well.
- some forms of obesity are characterized by a hypoactive hypothalmic-pituitary-adrenal axis.
- Some patients with post-traumatic stress syndrome have low cortisol excretion.
- Some patients undergoing withdrawal from smoking have decreased excretion of adrenaline and noradrenaline, as well as decreased amounts of cortisol in blood.
- corticotropin-releasing factor is the major regulator of the hypothalmic- pituitary-adrenal axis. Treatments for these disorders typically have poor efficacy.
- the present invention exploits the correlation of reduced levels of corticotropin-releasing factor with various neurophysiologically based disorders to effectively treat such conditions by increasing levels of free corticotropin-releasing factor through administration of inhibitors of the corticotropin-releasing factor/corticotropin-releasing factor binding protein complex.
- the present invention provides the novel compounds of Formula
- R 1 and R la are Ci-Cio alkyl, aryl(C ⁇ -C ⁇ o alkylenyl)-, furyl(C ⁇ -C ⁇ o alkylenyl)-, thienyl(C ⁇ -C ⁇ o alkylenyl)-, or pyrrolyl(C ⁇ -C ⁇ o alkylenyl)-;
- A is -S- or -NH-, or A is a monocyclic or bicyclic heterocyclic group containing one or more nitrogen atoms in which A is bound through a nitrogen; said heterocyclic group being optionally substituted with one or more moieties selected from the group consisting of heterocyclic, Ci-Ce alkyl, Ci-Ce alkoxy, heterocyclic(carbonyl)C ⁇ -C6 alkylenyl-, C3-C8 cycloalkyl, and phenyl,
- phenyl group may be substituted with one, two, or three moieties selected from the group consisting of halo, trifluoromethyl, hydroxy, Ci-Ce alkyl, and Ci-Ce alkoxy;
- R 2 is hydrogen, C1-C10 alkyl, C3-C10 cycloalkyl, aryl, heterocyclic, heterocyclic(C ⁇ -C ⁇ o alkylenyl)-, aryl(C ⁇ -C ⁇ o alkylenyl)-, or trityl,
- aryl, heterocyclic, heterocyclic(C ⁇ -C ⁇ o alkylenyl)-, or aryl(C ⁇ - C10 alkylenyl)- groups being substituted with one or more moieties selected from the group consisting of phenyl, CI-CG alkyl, hydroxy, Ci-Ce alkoxy, halo, trifluoromethyl,
- phenyl group may be substituted with one, two, or three moieties selected from the group consisting of halo, trifluoromethyl, hydroxy, Ci-Ce alkyl, and Ci-Ce alkoxy;
- R 2 is hydrogen
- R 2 is hydrogen only when A is a monocychc or bicyclic heterocyclic group
- the present invention provides methods of treating a condition associated with a deficiency of corticotropin-releasing factor comprising administering to a mammal in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof.
- This invention also provides pharmaceutical formulations comprising a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients therefor.
- the current invention concerns the discovery that a select group of substituted thiadiazines, those of Formula I, are useful in the treatment of conditions associated with corticotropin-releasing factor.
- Ci- Cio alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy and the like.
- the term "Ci-Cio alkoxy” includes within its definition the terms “Ci-C ⁇ alkoxy” and "C 1 -C3 alkoxy”.
- the term "C 1 -C 10 alkyl” refers to straight or branched, monovalent, saturated aliphatic chains of 1 to 10 carbon atoms and includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, and hexyl.
- C 1 -C10 alkyl includes within its definition the terms “Ci-C ⁇ alkyl” and “C 1 -C4 alkyl”.
- C 3 -C 8 cycloalkyl represents a saturated hydrocarbon ring structure containing from three to eight carbon atoms. Typical C3-C 8 cycloalkyl groups include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
- “Halo” represents chloro, fluoro, bromo or iodo.
- C 1 -C 1 0 alkylthio represents a straight or branched alkyl chain having from one to ten carbon atoms attached to a sulfur atom.
- Typical C 1 -C 10 alkylthio groups include methylthio, ethylthio, propylthio, isopropylthio, butylthio and the like.
- the term “C 1 -C 1 0 alkylthio” includes within its definition the term “Ci-C ⁇ alkylthio" and "C 1 -C3 alkylthio".
- C 1 -C 1 0 alkylenyl refers to a straight or branched, divalent, saturated aliphatic chains of 1 to 10 carbon atoms and includes, but is not limited to, methylenyl, ethylenyl, propylenyl, isopropylenyl, butylenyl, isobutylenyl, i-butylenyl, pentylenyl, isopentylenyl, hexylenyl, octylenyl, 3- methyloctylenyl, decylenyl.
- the term "Ci-C ⁇ alkylenyl” is encompassed within the term "C 1 -C 10 alkylenyl”.
- C 1 -C 1 0 alkylamino represents a group of the formula -NH(C ⁇ -C ⁇ o alkyl) wherein a chain having from one to ten carbon atoms is attached to an amino group.
- Typical C 1 -C4 alkylamino groups include methylamino, ethylamino, propylamino, isopropylamino, butylamino, sec-butylamino and the like.
- C2-C 1 0 alkenyl represents a straight or branched, monovalent, unsaturated aliphatic chain having from two to ten carbon atoms.
- Typical C2-C 1 0 alkenyl groups include ethenyl (also known as vinyl), 1-methylethenyl, 1 -methyl- 1-propenyl, 1-butenyl, 1-hexenyl,
- C2-C10 alkynyl represents a straight or branched, monovalent, unsaturated aliphatic chain having from two to ten carbon atoms with at least one triple bond.
- Typical C 2 -C 10 alkynyl groups include ethynyl, 1-methylethynyl, 1-propynyl, 1-butynyl, 1-hexynyl, 2-propynyl, 2-butynyl, 2-pentynyl, 2,4-dihexynyl, and the hke.
- C 3 -C 8 cycloalkenyl represents a hydrocarbon ring structure containing from three to eight carbon atoms and having at least one double bond within that ring, which is unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halo, halo(C ⁇ -C 4 alkyl), C 1 -C4 alkyl, C 1 -C 4 alkoxy, carboxy, C 1 -C4 alkoxycarbonyl, carbamoyl, N-(C ⁇ -C 4 alkyl)carbamoyl, amino, C 1 -C 4 alkylamino, di(C ⁇ -C4 alkyl)amino or -(CH 2 ) a -R y where a is 1, 2, 3 or 4 and R is hydroxy, C 1 -C 4 alkoxy, carboxy, C 1 -C4 alkoxycarbonyl, amino, carbamoyl, C 1 -C 4 alkylamino or di(C ⁇ -C 4
- amino-protecting group refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups on the compound.
- amino-protecting groups include formyl, trityl (herein abbreviated as "Tr"), phthalimido, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl, and urethane-type blocking groups such as benzyloxycarbonyl, 4-phenylbenzyloxycarbonyl, 2-methylbenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-fluorobenzyloxycarbonyl, 4-chlorobenzyloxycarbonyl, 3-chlorobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2 ,4-dichlorobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 3-bromobenzyl, 3-bromobenzyl, 3-bro
- amino-protecting group employed is usually not critical so long as the derivatized amino group is stable to the condition of subsequent reactions on other positions of the intermediate molecule and can be selectively removed at the appropriate point without disrupting the remainder of the molecule including any other amino-protecting groups.
- Preferred amino-protecting groups are trityl, f -butoxycarbonyl (t-BOC), allyloxycarbonyl and benzyloxycarbonyl.
- carboxy -protecting group refers to substituents of the carboxy group commonly employed to block or protect the carboxy functionality while reacting other functional groups on the compound.
- carboxy-protecting groups include methyl, jo-nitrobenzyl, p-methylbenzyl, p-methoxy -benzyl, 3,4-dimethoxybenzyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl, 2,4,6-trimethylbenzyl, pentamethylbenzyl, 3,4-methylenedioxybenzyl, benzhydryl, 4,4'-dimethoxybenzhydryl, 2,2',4,4'-tetramethoxybenzhydryl, -butyl, £-amyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, 4,4',4"-trimethoxy
- hydroxy -protecting groups refers to substituents of the hydroxy group commonly employed to block or protect the hydroxy functionality while reacting other functional groups on the compound. Examples of such hydroxy-protecting groups include methoxymethyl, benzyloxymethyl, methoxyethoxymethyl,
- 'leaving group refers to a group of atoms that is displaced from a carbon atom by the attack of a nucleophile in a nucleophOic substitution reaction.
- the term "leaving group” as used in this document encompasses, but is not limited to, activating groups.
- activating groups are well-known to those skilled in the art and may be, for example, succinimidoxy, phthalimidoxy, benzotriazolyloxy, benzenesulfonyloxy, methanesulfonyloxy, toluenesulfonyloxy, azido, or -0-CO-(C4-C7 alkyl).
- the compounds of the present invention are derivatives of 2,3,5,6-tetrahydro-l,2,6-thiadiazin-3,5-dione 1,1-dioxide which are named and numbered according to the RING INDEX, The American Chemical Society, as follows.
- the compounds of the present invention may have one or more asymmetric centers. As a consequence of these chiral centers, those compounds of the present invention occur as racemates, mixtures of enantiomers and as individual enantiomers, as well as diastereomers and mixtures of diastereomers. All asymmetric forms, individual isomers and combinations thereof, are within the scope of the present invention.
- the terms "R” and “S” are used herein as commonly used in organic chemistry to denote specific configuration of a chiral center.
- the term “R” (rectus) refers to that configuration of a chiral center with a clockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
- S refers to that configuration of a chiral center with a counterclockwise relationship of group priorities (highest to second lowest) when viewed along the bond toward the lowest priority group.
- the priority of groups is based upon their atomic number (in order of decreasing atomic number).
- a partial list of priorities and a discussion of stereochemistry is contained in NOMENCLATURE OF ORGANIC COMPOUNDS: PRINCIPLES AND PRACTICE, (J.H. Fletcher, et al.. eds., 1974) at pages 103-120.
- the older D-L system may also be used in this document to denote absolute configuration, especially with reference to amino acids.
- a Fischer projection formula is oriented so that the number 1 carbon of the main chain is at the top.
- the prefix "D” is used to represent the absolute configuration of the isomer in which the functional (determining) group is on the right side of the carbon atom at the chiral center and "L", that of the isomer in which it is on the left.
- the skilled practitioner can proceed by one of two routes.
- the practitioner may first prepare the mixture of enantiomers and then separate the two enantiomers.
- a commonly employed method for the resolution of the racemic mixture (or mixture of enantiomers) into the individual enantiomers is to first convert the enantiomers to diastereomers by way of forming a salt with an optically active salt or base. These diastereomers can then be separated using differential solubility, fractional crystallization, chromatography, or like methods. Further details regarding resolution of enantiomeric mixtures can be found in J. Jacques, et al.. ENANTIOMERS, RACEMATES, AND RESOLUTIONS, (1991).
- this invention may also choose an enantiospecific protocol for the preparation of the compounds of Formula I.
- a protocol employs a synthetic reaction design which maintains the chiral center present in the starting material in a desired orientation.
- These reaction schemes usually produce compounds in which greater than 95 percent of the title product is the desired enantiomer.
- this invention includes the pharmaceutically acceptable salts of the compounds defined by Formula I.
- a compound of this invention can possess a sufficiently acidic, a sufficiently basic, or both functional groups, and accordingly react with any of a number of organic and inorganic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to salts of the compounds of the above formula which are substantially non-toxic to living organisms.
- Typical pharmaceutically acceptable salts include those salts prepared by reaction of the compounds of the present invention with a pharmaceutically acceptable mineral or organic acid or an organic or inorganic base. Such salts are known as acid addition and base addition salts.
- Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as jD-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like
- organic acids such as jD-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- salts examples include the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, hydrochloride, dihydrochloride, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, phthalate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate
- Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen carries a suitable organic group such as an alkyl, alkenyl, alkynyl, or aralkyl moiety.
- Base addition salts include those derived from inorganic bases, such as ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like. Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- the potassium and sodium salt forms are particularly preferred.
- any salt of this invention is usually not of a critical nature, so long as the salt as a whole is pharmacologically acceptable and as long as the counterion does not contribute undesired qualities to the salt as a whole.
- This invention further encompasses the pharmaceutically acceptable solvates of the compounds of Formulas I.
- Many of the Formula I compounds can combine with solvents such as water, methanol, ethanol and acetonitrile to form pharmaceutically acceptable solvates such as the corresponding hydrate, methanolate, ethanolate and acetonitrilate.
- a prodrug is a drug which has been chemically modified and may be biologically inactive at its site of action, but which may be degraded or modified by one or more enzymatic or other in vivo processes to the parent bioactive form.
- This prodrug should have a different pharmacokinetic profile than the parent, enabhng easier absorption across the mucosal epithelium, better salt formation or solubility, or improved systemic stability (an increase in plasma half-life, for example).
- chemical modifications include:
- ester or amide derivatives which may be cleaved by esterases or lipases;
- the compounds of the present invention are prepared by reacting a compound of Formula II
- a trialkylorthoformate preferably triethylorthoformate
- a reactively available amine or thiol is generally performed in a lower alkylalcohol. Especially preferred is isopropanol.
- This reaction is generally performed at a temperature greater than 30°C, although other temperatures may be employed. This reaction is generally performed at the reflux temperature of the solvent employed.
- the compounds of Formula II are prepared essentially as described in A. Herrero, et al.. Archives in Pharmacology (Weinhei ⁇ i). 325:509-514 (1992) in which an N,N-bis(substituted)sulfamide is reacted with malonyl chloride.
- the crude material was purified by preparative high performance hquid chromatography over silica gel, eluting with 5 to 60% ethyl acetate in hexanes over a 25 minute gradient to yield of 2,6-diethyl-2,3,5,6-tetrahydro-2,3,5,6-tetrahydro- l,2,6-thiadiazin-3,5-dione 1,1-dioxide (35 g, 159.1 mmol).
- the present invention provides methods for increasing the level of free corticotropin-releasing factor in the brain through the administration of a hgand inhibitor of a corticotropin-releasing factor/corticotropin-releasing factor-binding protein complex.
- the increase in the level of free corticotropin- releasing factor may be measure by in vitro assays, such as ELISA, stimulation of ACTH release, or stimulation of cAMP production. In any of those assays, an increase in free corticotropin-releasing factor due to administration of the hgand inhibit is measured relative to a reference hgand inhibitor, usually recombinantly produced hamster corticotropin-releasing factor-binding protein (6-33).
- a preferred mode of screening candidate hgand inhibitors is by an in vitro hgand immunoradiometric assay (LIRMA).
- LIRMA corticotropin-releasing factor -binding protein may be isolated from brain tissue, serum, or cells expressing a recombinant form. This procedure is described in S. Sutton, et al. Endocrinology. 136:1097-1102 (1995). The isolated corticotropin-releasing factor is added to wells of a 96-well plate, to small polypropylene microfuge tubes, or to glass borosilicate tubes in a binding buffer (0.02% NP-40 in 50 mM phosphate-buffered saline).
- Radiolabeled ( 125 I) corticotropin-releasing factor and the candidate hgand inhibitor (10 ⁇ M) are added, and the reaction is incubated for one hour at room temperature.
- An appropriately diluted anti-corticotropin-releasing factor -binding protein antibody, such as rabbit, is added to each tube and, after further incubation, bound complexes are precipitated by the further addition of a goat anti-rabbit antibody.
- the precipitate containing 125 I-CRF is collected by centrifugation and the amount of radioactivity in the pellet id determined.
- Maximum inhibition (i.e., 100%) of the binding of the radiolabeled corticotropin-releasing factor to the binding protein is defined by the amount of radioactivity left in the pellets after incubation with 10 ⁇ M of the peptide hgand recombinantly produced hamster corticotropin-releasing factor-binding protein (6-33).
- the compounds of Formula I demonstrated efficacy as inhibitors of the corticotropin-releasing factor/corticotropin-releasing factor-binding protein compound.
- the compounds of Formula I are useful in treating conditions associated with decreased levels of corticotropin-releasing factor.
- diseases of syndromes include symptoms of dementia or learning and memory loss, obesity, chronic fatigue syndrome, atypical depression, post- partum depression, premenstrual syndrome (or late luteal phase disorder) seasonal depression, hypothyroidism, post-traumatic stress syndrome, nicotine withdrawal, vulnerability to inflammatory diseases.
- the compounds of Formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.
- the present invention also includes methods employing pharmaceutical compositions which contain, as the active ingredient, the compounds of Formula I associated with pharmaceutically acceptable carriers.
- the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container.
- the excipient serves as a diluent, it can be a solid, semi- solid, or hquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, ehxirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a hquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- the active compound In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalhne cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents.
- compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- the compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient.
- unit dosage form refers to physically discrete units suitable as unitary dosages dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- the active compound is effective over a wide dosage range.
- dosages per day normally fall within the range of about 0.5 to about 30 mg/kg of body weight. In the treatment of adult humans, the range of about 1 to about 15 mg/kg/day, in single or divided dose, is especially preferred.
- the amount of the compound actually administered will be determined by a physician, in the hght of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and therefore the above dosage ranges are not intended to hmit the scope of the invention in any way.
- dosage levels below the lower hmit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several smaller doses for administration throughout the day.
- sohd preformulation composition containing a homogeneous mixture of a compound of the present invention.
- the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This sohd preformulation is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- hquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as ehxirs and similar pharmaceutical vehicles.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the hquid or sohd compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in preferably pharmaceutically acceptable solvents may be nebuhzed by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebuhzing device may be attached to a face mask, tent, or intermittent positive pressure breathing machine.
- Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- the following examples illustrate the pharmaceutical compositions of the present invention.
- Hard gelatin capsules containing the following ingredients are prepared:
- the above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
- a tablet formula is prepared using the ingredients below:
- a dry powder inhaler formulation is prepared containing the following components:
- the active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling apphance.
- Tablets each containing 30 mg of active ingredient, are prepared as follows:
- Quantity Ingredient (mg/tablet)
- the active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.
- the solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve.
- the granules so produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve.
- the sodium carboxymethyl starch, magnesium stearate, and talc previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
- Capsules each containing 40 mg of medicament are made as follows:
- Quantity Ingredient (mg/capsule)
- the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.
- Suppositories each containing 25 mg of active ingredient are made as follows:
- the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
- Suspensions each containing 50 mg of medicament per 5.0 ml dose are made as follows:
- Capsules each containing 15 mg of medicament, are made as follows:
- Quantity Ingredient (mg/capsule)
- the active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425 mg quantities.
- An intravenous formulation may be prepared as follows:
- a topical formulation may be prepared as follows
- the white soft paraffin is heated until molten.
- the hquid paraffin and emulsifying wax are incorporated and stirred until dissolved.
- the active ingredient is added and stirring is continued until dispersed.
- the mixture is then cooled until sohd.
- Sublingual or buccal tablets each containing 10 mg of active ingredient, may be prepared as follows:
- the glycerol, water, sodium citrate, polyvinyl alcohol, and polyvinylpyrrolidone are admixed together by continuous stirring and maintaining the temperature at about 90°C.
- the solution is cooled to about 50-55°C and the medicament is slowly admixed.
- the homogenous mixture is poured into forms made of an inert material to produce a drug-containing diffusion matrix having a thickness of about 2-4 mm. This diffusion matrix is then cut to form individual tablets having the appropriate size.
- transdermal dehvery devices Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
- transdermal patches for the dehvery of pharmaceutical agents is well known in the art. See, e.g.. U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference.
- patches may be constructed for continuous, pulsatile, or on demand dehvery of pharmaceutical agents.
- Indirect techniques usually involve formulating the compositions to provide for drug latentiation by the conversion of hydrophilic drugs into lipid-soluble drugs or prodrugs.
- Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more hpid soluble and amenable to transportation across the blood-brain barrier.
- the dehvery of hydrophihc drugs may be enhanced by intra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73868/98A AU7386898A (en) | 1997-05-16 | 1998-05-14 | Thiadiazinyl corticotropin-releasing factor binding protein ligand inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4674197P | 1997-05-16 | 1997-05-16 | |
US60/046,741 | 1997-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998051312A1 true WO1998051312A1 (en) | 1998-11-19 |
Family
ID=21945125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/009861 WO1998051312A1 (en) | 1997-05-16 | 1998-05-14 | Thiadiazinyl corticotropin-releasing factor binding protein ligand inhibitors |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7386898A (en) |
WO (1) | WO1998051312A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3764322A (en) * | 1970-08-27 | 1973-10-09 | Agfa Gevaert Ag | Photography dry copying process with a merocyanine dye |
US4443587A (en) * | 1981-02-27 | 1984-04-17 | Abitz, Morf, Gritschneder | 1,2,6-Thiadiazine-3,5-dione-1,1-dioxides and their use as polymerization accelerators |
US4709027A (en) * | 1986-06-25 | 1987-11-24 | American Home Products Corporation | Bicyclic spirosulfonimides with psychotropic activity |
US4771048A (en) * | 1986-07-12 | 1988-09-13 | Bayer Aktiengesellschaft | Use of thiadiazinones for combating endoparasites |
US5194440A (en) * | 1991-02-27 | 1993-03-16 | Merck Sharp & Dohme Ltd. | Substituted cyclic sulphamide derivatives |
-
1998
- 1998-05-14 AU AU73868/98A patent/AU7386898A/en not_active Abandoned
- 1998-05-14 WO PCT/US1998/009861 patent/WO1998051312A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3764322A (en) * | 1970-08-27 | 1973-10-09 | Agfa Gevaert Ag | Photography dry copying process with a merocyanine dye |
US4443587A (en) * | 1981-02-27 | 1984-04-17 | Abitz, Morf, Gritschneder | 1,2,6-Thiadiazine-3,5-dione-1,1-dioxides and their use as polymerization accelerators |
US4544742A (en) * | 1981-02-27 | 1985-10-01 | Werner Schmitt | 1,2,6-Thiadiazine-3,5-dione-1,1-dioxides |
US4709027A (en) * | 1986-06-25 | 1987-11-24 | American Home Products Corporation | Bicyclic spirosulfonimides with psychotropic activity |
US4771048A (en) * | 1986-07-12 | 1988-09-13 | Bayer Aktiengesellschaft | Use of thiadiazinones for combating endoparasites |
US5194440A (en) * | 1991-02-27 | 1993-03-16 | Merck Sharp & Dohme Ltd. | Substituted cyclic sulphamide derivatives |
Non-Patent Citations (1)
Title |
---|
HERRERO A., ET AL.: "SYNTHESIS AND ANTIPROTOZOAL PROPERTIES OF 1,2,6-THIADIAZINE 1,1- DIOXIDE DERIVATIVES.", ARCHIV DER PHARMAZIE, WILEY VERLAG, WEINHEIM, vol. 325., no. 08., 1 February 1992 (1992-02-01), Weinheim, pages 509 - 514., XP002914153, ISSN: 0365-6233, DOI: 10.1002/ardp.19923250811 * |
Also Published As
Publication number | Publication date |
---|---|
AU7386898A (en) | 1998-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1370552B1 (en) | Rho-kinase inhibitors | |
RU2140921C1 (en) | Nonpeptide antagonists of tachikinin receptors | |
ES2390937T3 (en) | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | |
US8153630B2 (en) | Kinase inhibitors | |
WO1996031214A1 (en) | 2-acylaminopropanamides as tachykinin receptor antagonists | |
PL207384B1 (en) | Benzothiazole derivatives | |
EP0686629A2 (en) | Cyclohexyl tachykinine receptor antagonists | |
JP2010013459A (en) | Use of oxy-indole derivative in treatment of dementia-associated disease, alzheimer disease and glycogen synthase kinase-3-associated symptom | |
US7501416B2 (en) | Quinoxaline compounds and methods of using them | |
WO1997025041A1 (en) | Benzimidzolyl neuropeptide y receptor antagonists | |
KR101158568B1 (en) | Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration | |
BR122016014302A2 (en) | process to prepare a salt | |
EA016251B1 (en) | 8-PIPERIDINYL-2-PYRIDINYL-PYRIMIDO [1,2-a] PIRIMIDIN-4-ONE DERIVATIVES | |
JP2010526867A (en) | Arylamidopyrimidone compounds | |
EP0761219A1 (en) | 2-Acylaminopropanamines as growth hormone secretagogues | |
KR20140051823A (en) | Crystalline oxazine derivative and its use as bace inhibitor | |
TW200904436A (en) | Arylamide pyrimidone derivatives | |
CN102811998A (en) | New Inhibitors Of Cyclophilins And Uses Thereof | |
DE60013639T2 (en) | CALCIUM SALT OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PREPARING THE SALTS AND MEDICAMENTS CONTAINING THEM | |
US11447497B2 (en) | (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases | |
US6255494B1 (en) | Benzimidzolyl neuropeptide Y receptor antagonists | |
EP4052706A1 (en) | Composition for preventing or inhibiting axonal degeneration | |
CA3094481A1 (en) | Phenothiazine derivatives and uses thereof | |
WO1998051312A1 (en) | Thiadiazinyl corticotropin-releasing factor binding protein ligand inhibitors | |
KR100882925B1 (en) | Pharmaceutical compositions containing pyrazole derivatives for treating as serotonin antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09403859 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998549542 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |